Loading...
Both companies sell diabetes and obesity medicines, especially GLP-1 drugs like Ozempic/Wegovy at Novo Nordisk and Mounjaro/Zepbound at Eli Lilly. They are fighting for the same patients, doctors, and insurance coverage in one of the biggest drug markets in the world.
As of Jun 29, 2026
For informational purposes only.
Eli Lilly’s stock added another small step up today, finishing around $1,230, after a huge jump late last week. If you own it, you’re basically riding the aftershock of several pieces of good news that all point in the same direction: more demand for Lilly’s drugs, and a stronger pipeline beyond weight loss. If you’re just watching from the sidelines, the main takeaway is that this is now a “priced for big success” story, not a quiet, under‑the‑radar one.
The share price rose about 2% today, on trading volume that was only slightly above normal. That’s different from Friday, when the stock spiked more than 7% on very heavy trading and hit an all‑time high.
Put simply: Friday was the big “burst of excitement”; today looked more like buyers and sellers settling in, with buyers still slightly stronger. The stock is now sitting near the very top of its recent 1‑month range, which means people have been willing to pay more and more for it in a short time.
One risk of that kind of sharp rise is that there isn’t much recent “floor” under the price. The nearest technical support (a level where traders previously stepped in to buy) is far below today’s price, so if sentiment sours, the drop could be noticeable before it finds a new base.
There are three main drivers behind Lilly’s recent move:
